Literature DB >> 10853680

Treadmill exercise-induced release of endothelin-1 in patients with peripheral arterial occlusive disease at Fontaine stage IIb.

R A Mangiafico1, L S Malatino, R S Spada, M Santonocito, R Messina, S Dell'Arte, T Attinà.   

Abstract

BACKGROUND: Endothelin-1 (ET-1) is an endothelial vasoconstrictor mitogenic peptide which is thought to be a marker of endothelial damage and a potential participant in the pathophysiological processes of the development of atherosclerotic lesions and disease states associated with vasoconstriction and vasospasm.
METHODS: To investigate the endothelin-1 release in response to dynamic exercise in patients with peripheral arterial occlusive disease (PAOD), plasma concentrations were determined by radioimmunoassay in 16 patients (14 men, 2 women, mean age 56.2 +/- 8.1 years) with peripheral arterial occlusive disease at Fontaine stage IIb and in 10 control subjects (8 men, 2 women, mean age 58.1 +/- 7.2 years) in normal health during treadmill testing (slope 5%, speed 3 km/hr). Blood samples were collected at rest from an antecubital vein, at the onset of claudication pain, and 10 minutes after exercise.
RESULTS: Mean plasma endothelin-concentrations during the stress test increased significantly in the patients with arterial disease, rising from basal values of 4.4 +/- 0.6 pmol/L to values of 8.9 +/- 0.7 pmol/L at the end of the test (p < 0.0001), whereas it did not change significantly in control subjects (rising from 2.6 +/- 0.4 pmol/L to 2.7 +/- 0.5 pmol/L). Further, plasma endothelin- in the patients with arterial disease was at all times higher than in the control subjects (p < 0.0001).
CONCLUSIONS: In conclusion, this study shows that in patients with peripheral arterial occlusive disease, plasma endothelin-1 increases after treadmill exercise performed until claudication pain supervenes. Raised endothelin-1 could be a marker of ischaemic acute endothelial damage and/or could contribute to increase the vascular resistance in ischaemic limbs of these patients during dynamic exercise by promoting arterial/arteriolar vasoconstriction or vasospasm.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10853680

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  6 in total

1.  Recovery dynamics of skeletal muscle oxygen uptake during the exercise off-transient.

Authors:  Brad J Behnke; Leonardo F Ferreira; P J McDonough; Timothy I Musch; David C Poole
Journal:  Respir Physiol Neurobiol       Date:  2009-07-18       Impact factor: 1.931

Review 2.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

3.  Oxygen availability and skeletal muscle oxidative capacity in patients with peripheral artery disease: implications from in vivo and in vitro assessments.

Authors:  Corey R Hart; Gwenael Layec; Joel D Trinity; Yann Le Fur; Jayson R Gifford; Heather L Clifton; Russell S Richardson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-22       Impact factor: 4.733

4.  Acute effects of leg heat therapy on walking performance and cardiovascular and inflammatory responses to exercise in patients with peripheral artery disease.

Authors:  Jacob C Monroe; Qifan Song; Michael S Emery; Daniel M Hirai; Raghu L Motaganahalli; Bruno T Roseguini
Journal:  Physiol Rep       Date:  2021-01

5.  Correlations between plasma endothelin-1 levels and breakthrough pain in patients with cancer.

Authors:  Xue-Bin Yan; Tuo-Chao Peng; Dong Huang
Journal:  Onco Targets Ther       Date:  2015-12-08       Impact factor: 4.147

Review 6.  Lower extremity arterial disease in patients with diabetes: a contemporary narrative review.

Authors:  Mathilde Nativel; Louis Potier; Laure Alexandre; Laurence Baillet-Blanco; Eric Ducasse; Gilberto Velho; Michel Marre; Ronan Roussel; Vincent Rigalleau; Kamel Mohammedi
Journal:  Cardiovasc Diabetol       Date:  2018-10-23       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.